Depomed Inc. July 29 announced it has acquired all U.S. and Canadian rights to Lazanda (fentanyl) nasal spray from Archimedes Pharma Ltd.
Lazanda is indicated for managing breakthrough pain in cancer patients 18 years old and older who are receiving and are tolerant to opioid therapy for persistent cancer pain. The Food and Drug Administration approved the drug in 2011 (9 PLIR 863, 7/8/11).
Depomed said it acquired the rights for $4 million in cash, royalties on net sales, potential milestone payments based on increased sales, and assumption of certain liabilities.
Sales of Lazanda in the United States ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.